Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
ucb.com

See what CB Insights has to offer

Investments

8

Portfolio Exits

12

Partners & Customers

10

Service Providers

1

About UCB

UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.

UCB Headquarter Location

Allee de la Recherche, 60

Brussels, 1070,

Belgium

+32 (0)2 559 99 99

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing UCB

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find UCB in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

260 items

UCB Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

UCB Rank

Latest UCB News

Citrate-free Taltz now available

Aug 8, 2022

Disclosures: Armstrong reports receiving research grants and personal fees from Bristol Myers Squibb, Eli Lilly, Janssen, Leo Pharma and Novartis; personal fees from Boehringer Ingelheim/Parexel, Celgene, Dermavant, Genentech, GlaxoSmithKline, Menlo Therapeutics, Merck, Modernizing Medicine, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Science 37, Sun Pharma and Valeant; and grants outside of the submitted work from Dermira, Kyowa Hakko Kirin and UCB. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio A citrate-free formulation of Taltz injection for patients is now available following its FDA approval earlier this year, Eli Lilly and Company announced in a press release. The new formulation of Taltz (ixekizumab) 80 mg/mL injection showed significantly reduced injection site pain and an 86% decrease in VAS compared with the original formulation. Citrate-free Taltz injections are now available for patients with plaque psoriasis, psoriatic arthritis, spondylitis and non-radiographic axial spondylarthritis. Taltz is approved for adults and children with severe plaque psoriasis, adults with active psoriatic arthritis, active ankylosing spondylitis and active non-radiographic axial spondylarthritis . “Today is an exciting milestone for the nearly 30 million people around the world who live with the challenging symptoms of these autoimmune diseases that affect the skin and joints,” April W. Armstrong, MD, MPH, professor of dermatology and associate dean of clinical research, Keck School of Medicine at the University of Southern California, said in the release. “In my six years of prescribing Taltz, I’ve seen firsthand the significant impact Taltz has had for patients across multiple indications. The availability of Taltz as a citrate-free formulation represents an important advance in patient care that will allow more patients to experience less injection-site pain.” A new prescription is not needed for patients already receiving therapy with Taltz. The new formulation will be shipped across the United States with widespread availability expected by the end of August. Additionally, the European Medicines Agency approved the citrate-free version of the drug in late 2021. Read more about

UCB Investments

8 Investments

UCB has made 8 investments. Their latest investment was in Nile AI as part of their Series A on January 1, 2021.

CBI Logo

UCB Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/14/2021

Series A

Nile AI

$29.3M

Yes

4

8/15/2019

Series B

Subscribe to see more

$99M

Subscribe to see more

10

9/25/2018

Series B

Subscribe to see more

$99M

Subscribe to see more

10

2/9/2018

Series A

Subscribe to see more

$99M

Subscribe to see more

10

4/6/2016

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/14/2021

8/15/2019

9/25/2018

2/9/2018

4/6/2016

Round

Series A

Series B

Series B

Series A

Series B

Company

Nile AI

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$29.3M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

10

10

10

10

UCB Portfolio Exits

12 Portfolio Exits

UCB has 12 portfolio exits. Their latest portfolio exit was Syndesi Therapeutics on March 01, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/1/2022

Acquired

$99M

5

9/30/2019

Reverse Merger

$99M

2

8/6/2018

Divestiture

UCB - Innere Medizin

$99M

8/1/2018

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

2/1/2018

Spinoff / Spinout

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/1/2022

9/30/2019

8/6/2018

8/1/2018

2/1/2018

Exit

Acquired

Reverse Merger

Divestiture

Divestiture

Spinoff / Spinout

Companies

UCB - Innere Medizin

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

5

2

10

10

UCB Acquisitions

7 Acquisitions

UCB acquired 7 companies. Their latest acquisition was Zogenix on January 19, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/19/2022

Series C

$99M

$199M

Acq - Pending

3

11/12/2020

Subscribe to see more

$99M

Subscribe to see more

10

6/5/2020

Debt

Subscribe to see more

$99M

$99M

Subscribe to see more

10

4/2/2020

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

10

4/5/2018

Grant

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

1/19/2022

11/12/2020

6/5/2020

4/2/2020

4/5/2018

Investment Stage

Series C

Debt

Series B

Grant

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$199M

$99M

$99M

$99M

Note

Acq - Pending

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

UCB Partners & Customers

10 Partners and customers

UCB has 10 strategic partners and customers. UCB recently partnered with Roswell Biotechnologies on June 6, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

6/8/2022

Partner

United States

3

4/13/2022

Partner

United Kingdom

Ampersand Health and UCB partner in new arthritis initiative

Ampersand Health and UCB have announced a partnership to help patients with Axial Spondyloarthritis -- a form of inflammatory arthritis that mainly affects the joints of the spine .

1

4/13/2022

Partner

United States

1

4/4/2022

Partner

South Korea

Subscribe to see more

Subscribe to see more

10

3/8/2022

Vendor

United States

Subscribe to see more

Subscribe to see more

10

Date

6/8/2022

4/13/2022

4/13/2022

4/4/2022

3/8/2022

Type

Partner

Partner

Partner

Partner

Vendor

Business Partner

Country

United States

United Kingdom

United States

South Korea

United States

News Snippet

Ampersand Health and UCB partner in new arthritis initiative

Ampersand Health and UCB have announced a partnership to help patients with Axial Spondyloarthritis -- a form of inflammatory arthritis that mainly affects the joints of the spine .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

1

1

10

10

UCB Service Providers

1 Service Provider

UCB has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired, and Acq - P2P

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acquired, and Acq - P2P

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

UCB Team

35 Team Members

UCB has 35 team members, including current President, Duane H Barnes.

Name

Work History

Title

Status

Duane H Barnes

President

Current

Dhaval Patel

Novartis Venture Funds, Novartis, and Duke University

Executive Vice President

Current

Claire Brading

Managing Director

Current

Vincent Lenaerts

Chief Executive Officer

Former

Didier Malherbe

Chief Executive Officer

Former

Name

Duane H Barnes

Dhaval Patel

Claire Brading

Vincent Lenaerts

Didier Malherbe

Work History

Novartis Venture Funds, Novartis, and Duke University

Title

President

Executive Vice President

Managing Director

Chief Executive Officer

Chief Executive Officer

Status

Current

Current

Current

Former

Former

You May Also Like

L
LivaNova

LivaNova is a medical device company in the treatment of cardiovascular diseases. The company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders.

Novela Neurotechnologies Logo
Novela Neurotechnologies

Novela Neurotechnologies is a medical technology company developing hardware and software solutions that improve the lives of people suffering from neurological disorders.

Livongo Health Logo
Livongo Health

Livongo Health (NASDAQ: LVGO) offers a mobile monitoring platform that empowers people with chronic conditions such as diabetes, hypertension, weight management, diabetes prevention, and behavioral health issues to take action when it is most likely to have clinical benefits. Its team of data scientists aggregates and interprets substantial amounts of health data and information to create personalized and timely health signals for users.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.